Evaluation of herbal compound containing Anacyclus pyrethrum, Senna, Ferrula asafoetida and Terminalia chebula in COVID19

Evaluation of herbal compound containing Anacyclus pyrethrum, Senna, Ferrula asafoetida and Terminalia chebula in COVID19: A randomized clinical trial study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200522047545N1

Enrollment

200

Registered

2020-08-05

Start date

2020-07-31

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19. COVID-19

Interventions

Intervention group: In addition to the standard treatment (200 mg Hydroxychloroquine tablets or two 250 mg Chloroquine phosphate tablets), herbal tablets containing Anacyclus pyrethrum, Senna, Ferrula

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age: more than 18 Lab Analysis and CT-scan Patient consent The severity of the disease: mild to moderate

Exclusion criteria

Exclusion criteria: Patients with severe disease status Liver disease experience Pregnancy or breastfeeding Kidney failure Kidney transplantation experience Receiving any clinical trial medication in the last 30 days

Design outcomes

Primary

Measure	Time frame
Decreasing hospital stay days. Timepoint: At the end of the study. Method of measurement: Based on the date of hospitalization and discharge from the hospital.;Decreasing duration of symptoms presence. Timepoint: During and at the end of the study. Method of measurement: Based on the date of hospitalization and the date of dissolving of fever and improving of respiratory symptoms including dyspenea, cough and improving of O2 saturation during daily history taking and physical exams.;Hospital care and treatment costs. Timepoint: At the end of the study. Method of measurement: Based on patients' financial records (hospital stay days and etc.).	—

Measure

Time frame

Decreasing hospital stay days. Timepoint: At the end of the study. Method of measurement: Based on the date of hospitalization and discharge from the hospital.;Decreasing duration of symptoms presence. Timepoint: During and at the end of the study. Method of measurement: Based on the date of hospitalization and the date of dissolving of fever and improving of respiratory symptoms including dyspenea, cough and improving of O2 saturation during daily history taking and physical exams.;Hospital care and treatment costs. Timepoint: At the end of the study. Method of measurement: Based on patients' financial records (hospital stay days and etc.).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Mohammadzadeh

Tabriz University of Medical Sciences

mohammadzadeh.ra@tbzmed.ac.ir+98 41 3334 9591

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026